Dr. Usmani on the Potential Utility of Allogeneic CAR T-Cell Therapy in Multiple Myeloma

Video

Saad Z. Usmani, MD, FACP, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorders, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the potential utility of allogeneic CAR T-cell therapy in multiple myeloma.

Currently, the investigational, off-the-shelf CAR T-cell therapies ALLO-715 and ALLO-647 are being evaluated in clinical trials for patients with relapsed/refractory multiple myeloma. If these studies yield positive findings, allogeneic CAR T-cell therapies could offer a novel treatment approach for patients with relapsed/refractory multiple myeloma who have progressed on proteasome inhibitors, immunomodulatory agents, and CD38-directed antibodies.

Additionally, these products could offer more flexibility with regard to bridging therapy for CAR T-cell therapy, Usmani says. However, the overall utility of these products will depend on the capacity transplant and cellular therapy centers have to administer them, Usmani says. With bispecific antibodies also emerging in this space, more data are needed to inform how allogeneic CAR T-cell products could be integrated into clinical practice, Usmani concludes.

Related Videos
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
© 2024 MJH Life Sciences

All rights reserved.